Business Performance and Financial Updates - Preliminary fourth-quarter 2024 Rezdiffra net sales range between $100 million to $103 million, and full-year 2024 net sales range between $177 million to $180 million [4][5] - Preliminary year-end 2024 cash, cash equivalents, restricted cash, and marketable securities total approximately $931 million [4][5] - Over 11,800 patients were on Rezdiffra therapy as of year-end 2024 [4][5][13] Key Milestones and Achievements - Rezdiffra received U.S. FDA approval on March 14, 2024, becoming the first and only approved therapy for MASH [5] - The Phase 3 MAESTRO-NASH trial results were published in The New England Journal of Medicine and recognized as one of the 14 notable scientific research articles of 2024 [5] - EMA validated the Marketing Authorization Application (MAA) for Rezdiffra on March 5, 2024, with an anticipated decision in mid-2025 and a potential European launch starting in Germany in the second half of 2025 [5] - Enrollment for the MAESTRO-NASH OUTCOMES study, evaluating Rezdiffra in patients with compensated MASH cirrhosis, was completed on October 21, 2024 [5] Market Opportunity and Disease Overview - MASH is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, and premature mortality, and is expected to become the leading cause of liver transplantation in the U.S. [3][6] - Patients with moderate to advanced liver fibrosis (stages F2 to F3) have a 10-17 times higher risk of liver-related mortality compared to those without fibrosis, while those with cirrhosis face a 42 times higher risk [6] - An estimated 1.5 million patients in the U.S. have been diagnosed with MASH, with approximately 315,000 patients under the care of liver specialists having moderate to advanced fibrosis [7] Strategic Outlook and Growth Opportunities - The company is preparing for European expansion in the second half of 2025, pending EMA approval [5][13] - Positive results from the MAESTRO-NASH OUTCOMES trial could position Rezdiffra as the only treatment for F2 to F4 MASH and the only therapy with outcomes data this decade [13] Leadership and Communication - Bill Sibold, CEO of Madrigal, will present updates at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, via a live webcast [2][4]

Group 1 - The core viewpoint is that Madrigal Pharmaceuticals has experienced a significant stock increase of over 60% since April 2024, attributed to strong sales performance of its product Rezdiffra in the metabolic-associated steatohepatitis (MASH) market [1] - The first two quarters of Rezdiffra sales have exceeded estimates, indicating a successful product launch [1] Group 2 - The article emphasizes the importance of trading around key events such as trial results and NDA/BLA approvals in the biotech sector [1]

Company Presentation - Madrigal Pharmaceuticals will present at the 43rd Annual J P Morgan Healthcare Conference on January 15 2025 at 2 15 pm PT [1] - The presentation will be webcast live and accessible via Madrigalâs Investor Relations Site Events and Presentations [1] Company Overview - Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) a liver disease with significant unmet medical needs [2] - The companyâs lead medication Rezdiffra (resmetirom) is a once-daily oral liver-directed THR-β agonist designed to target key underlying causes of MASH [2] Contact Information - Investor inquiries can be directed to Tina Ventura at IR@madrigalpharma com [3] - Media inquiries can be directed to Christopher Frates at media@madrigalpharma com [3]

Madrigal Pharmaceuticals, Inc. (MDGL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MDGL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving av ...

Shares of Madrigal (MDGL) have gained 34.6% over the past four weeks to close the last trading session at $288.58, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $364.87 indicates a potential upside of 26.4%.The average comprises 15 short-term price targets ranging from a low of $155 to a high of $507, with a standard deviation of $81.13. While the lowest estimate indicates a d ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: UBS Global Healthcare Conference 2024Wednesday, November 13, 2024 at 2:00 P.M. ESTThe presentation will be webcast live and may be accessed here. 7th Annual Evercore HealthCONx ConferenceWednesday, December 4, 2024 at 9:35 A.M. EST Piper Sandler 36th Annual Healthcare ConferenceThursday, December 5, 2024 ...

Madrigal Pharmaceuticals (MDGL) reported third-quarter 2024 loss of $4.92 per share, narrower than the Zacks Consensus Estimate of a loss of $6.94 per share. In the year-ago quarter, the company reported a loss of $5.34 per share.During the quarter, the company generated total revenues of $62.2 million — entirely from product sales of its recently approved nonalcoholic steatohepatitis (NASH) drug Rezdiffra (resmetirom), which was commercially launched this April. The metric beat the Zacks Consensus Estimate ...

Financial Data and Key Metrics Changes - The company reported net sales of $62 million for Q3 2024, reflecting strong demand and exceeding expectations [7][35] - R&D expenses for Q3 2024 were $68.7 million, down from $71 million in Q3 2023, indicating stable R&D spending [39] - SG&A expenses increased to $107.6 million from $27.6 million in Q3 2023, primarily due to the expansion of commercial operations following Rezdiffra's approval [39] - The company had $1 billion in cash and marketable securities as of September 30, 2024, providing a strong financial position to support ongoing operations [40] Business Line Data and Key Metrics Changes - The launch of Rezdiffra has seen over 6,800 patients on the drug by the end of Q3 2024, a significant increase from over 2,000 patients at the end of Q2 2024 [10] - The company achieved coverage for more than 80% of commercial lives for Rezdiffra, ahead of schedule [13] - Approximately 40% of top prescribers have prescribed Rezdiffra, doubling the penetration rate from the previous quarter [17] Market Data and Key Metrics Changes - The company is targeting 315,000 patients diagnosed with NASH with moderate to advanced fibrosis, with only 2% currently on treatment [25] - The market for NASH treatment is expected to expand significantly, with the potential for combination therapies as 25% of Rezdiffra patients are already using it alongside GLP-1s for comorbidities [27] Company Strategy and Development Direction - The company aims to strengthen its leadership position in the NASH market through the successful launch of Rezdiffra and plans for a European launch in the second half of 2025 [29] - The company is focused on building a pipeline beyond Rezdiffra, looking for opportunities in NASH and potential combination therapies [119] - The management emphasizes the importance of establishing Rezdiffra as the foundational therapy for NASH, supported by positive clinical outcomes and real-world data [22][34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future market dynamics, citing Rezdiffra's strong product profile and the significant opportunity to penetrate the target market [28] - The management noted that the early launch metrics are crucial indicators of future success, with growth tracking well against benchmarks from other successful specialty medicine launches [45] - The company is preparing for potential competition from GLP-1 therapies, which could further accelerate the growth opportunity for Rezdiffra [25][26] Other Important Information - The company completed enrollment in its MAESTRO-NASH OUTCOMES trial, which could position Rezdiffra as the first therapy for patients with compensated NASH cirrhosis [30][31] - The company is enhancing its R&D capabilities with the appointment of Dr. Michael Charlton as Head of Clinical Development, a recognized expert in NASH [32] Q&A Session Summary Question: Future growth expectations for Q4 and 2025 - Management is pleased with the strong launch progress and anticipates growth in Q4 and 2025 based on current performance metrics [44][46] Question: Cadence of new patient starts - The company is steadily adding patients and prescribers, with expectations for continued growth as the market becomes more established [50] Question: Free drug program utilization - Very little free drug was utilized in the recent quarter, indicating strong coverage and access for patients [64] Question: Persistence and default rates for patients - Management is optimistic about early patient persistence but will need more time to quantify specific rates [116] Question: Business development strategy - The company aims to build a pipeline focused on NASH and is open to evaluating new opportunities that align with its leadership position [119]

Table of Contents _________________________ _________________________ _________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 Par Value Per Share MDGL The NASDAQ Stock Market LLC _________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period e ...